Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors

被引：0
|
作者：
Yan Zhou
Jiankun Zhu
Haiya Wu
Yuying Deng
Qiuhe Ji
机构：
[1] Endocrinology Department of Xi’an International Medical Center Hospital,
[2] Lilly Suzhou Pharmaceutical Co. Ltd.,undefined
[3] Endocrinology Department of the First Affiliated Hospital (Xijing Hospital) of Air Force Medical University,undefined
来源：
Diabetes Therapy | 2021年 / 12卷
关键词：
Chinese patient; Dulaglutide; Pancreatic safety; Subgroup analysis; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2677 / 2690
页数：13
相关论文
共 50 条
  • [21] Efficacy and safety of once-weekly dulaglutide versus insulin glargine in Chinese patients with type 2 diabetes and different baseline glycaemic patterns
    Hou, J.
    Zhang, B.
    Li, Q.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S287 - S287
  • [22] Efficacy and Safety of Once-Weekly Dulaglutide vs. Once-Daily Liraglutide in Japanese Patients with Type 2 Diabetes
    Takamura, Toshinari
    Miyagawa, Jun-Ichiro
    Odawara, Masato
    Takita, Yasushi
    Iwamoto, Noriyuki
    Imaoka, Takeshi
    [J]. DIABETES, 2015, 64 : A285 - A285
  • [23] Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study
    Seo, Ji Young
    Lee, Cha Gon
    Choi, Hoonsung
    Lee, Hong Kyu
    Lee, So Young
    Kim, Hyo-Jeong
    Jung, Kyong Yeun
    Kim, Jin Taek
    [J]. ANNALS OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2023, 28 (04) : 296 - 301
  • [24] Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years
    Boustani, M. A.
    Pittman, I.
    Yu, M.
    Thieu, V. T.
    Varnado, O. J.
    Juneja, R.
    [J]. DIABETES OBESITY & METABOLISM, 2016, 18 (08): : 820 - 828
  • [25] Efficacy and Safety by Duration of Diabetes with Once-Weekly Dulaglutide in the AWARD Program
    Gallwitz, Baptist
    Pavo, Imre
    Thieu, Vivian
    Jia, Nan
    Zhang, Nan
    Garcia-Perez, Luis-Emilio
    [J]. DIABETES, 2016, 65 : A269 - A269
  • [26] Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
    Kugler, Anne J.
    Thiman, Michael L.
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2018, 11 : 187 - 197
  • [27] Efficacy of once-weekly dulaglutide on HbA1c reduction in East Asian patients with T2DM: subgroup analysis according to potential influencing factors
    Peng, Yongde
    Zhang, Bin
    Hou, Jianing
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [28] Influence on HbA1c and weight by baseline body mass index with once-weekly dulaglutide in Chinese patients with type 2 diabetes mellitus
    Shi, Yongquan
    Zhang, Bin
    Wu, Haiya
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [29] Commentary on "Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study"
    Lim, Han Hyuk
    [J]. ANNALS OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2023, 28 (04) : 235 - 236
  • [30] Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Once-Weekly Dulaglutide in Elderly Patients with Type 2 Diabetes (T2D)
    Loghin, Corina
    Schneck, Karen B.
    Cui, Xuewei
    Chien, Jenny Y.
    [J]. DIABETES, 2015, 64 : A259 - A259
12345